HSP90AB1 and neoplasm: STA9090, as a N-terminal inhibitor, was one of the very few inhibitors of Hsp90 that become a candidate of phase III clinical trials, had been shown to selectively target the more active Hsp90 in tumor cells, but having a lesser effect on nontumor cells (21, 22).